Is midostaurin effective in treating diseases?

Midostaurin (Midostaurin) is a tyrosine kinase inhibitor (TKI) widely used to treat acute myeloid leukemia (AML) and some other cancers. It inhibits intracellular tyrosine kinase, prevents the growth and spread of tumor cells, and blocks the division of cancer cells, thus exerting anti-cancer effects. In particular, midostaurin has a significant therapeutic effect on AML patients who are positive for Fms-related tyrosine kinase 3 (FLT3) mutations, which are a common poor prognostic factor in AML patients.

Midostaurin was originally approved to treat acute myeloid leukemia withFLT3 mutations, which are present in about one-third of AML patients and are associated with poor prognosis. FLT3 mutations promote the rapid growth of cancer cells by enhancing cell proliferation and inhibiting apoptosis. Midostaurin can effectively target these mutations, inhibit the activity of FLT3, prevent the growth of cancer cells, and thus improve the overall survival rate of patients.

In clinical trials approved by the FDA in the United Statesmidostaurin has been shown to improve treatment efficacy when used in combination with chemotherapy drugs, especially in patients with FLT3 mutation-positive AML. In a phase III clinical trial called "Ratify," patients treated with midostaurin in combination with standard chemotherapy drugs showed better survival and response rates than traditional treatment options, making midostaurin an important drug for the treatment of this type of AML. The trial results show that combination treatment with midostaurin can significantly extend the overall survival (OS) and disease-free survival (RFS) of patients.

In addition, midostaurin has also shown positive effects in the maintenance treatment of acute myeloid leukemia patients after stem cell transplantation. Although research in this area continues, early results show that midostaurin has the potential to prevent disease recurrence and prolong remission.

Reference materials:https://medlineplus.gov/druginfo/meds/a617033.html